Over the last decade there has been a proliferation in clinical trials to test agents for the treatment of erectile dysfunction (ED). Many aspects of clinical trials design and conduct and guidelines for future conduct have been the subject of a recent comprehensive review (Rosen R et al. In: Proceedings of the 1st International Consultation on Erectile Dysfunction 1999). The present article attempts to extend that analysis from trials that focus purely on symptomatic improvement of ED to trials relevant to the management of the ED patient in the community. Although the regulatory approval process accounts for the bulk of the clinical trials undertaken, studies are also initiated for concept testing, post-marketing surveillance and for promotional andaor pricing reasons. The trial design can be dependent on which of the above objectives is being served. However, there are also many common features that are summarized below; the major focus is placed on regulatory-standard or`pivotal' studies.
Design of clinical trials

Phases of clinical development
The process of drug development andaor regulatory approval involves several distinct phases. In addition to serving a regulatory function, the studies are intended to be predictive of likely risk ± bene®t in the general community.
Phase I studies are those that involve the ®rst exposure of the novel therapeutic entity to man. These are generally conducted in normal healthy individuals and unless there is a particular need, women of child-bearing age are generally excluded. Phase I studies generally include single and multiple-dose assessments of tolerability and pharmacokinetics of the new agent. Phase I evaluations may also involve clinical pharmacology studies using surrogate endpoints to help determine the optimal dose in the target population, but can also involve evaluations in special sub-populations (women and the elderly) if these populations are likely to be further evaluated in later-stage clinical development.
Although phase I studies using surrogate endpoints can give some index of ef®cacy, the ®rst true assessment of ef®cacy is usually captured in phase II. The prime objective of this phase is dose-setting, ie the identi®cation of dose(s) for evaluation in the much larger phase III studies. The outcome assessments used in phase II involve a mixture of objective measures (eg Rigiscan) or self-report measures (eg daily diaries and the International Index of Erectile Function, IIEF), which are described later in more detail.
Most frequently, a crossover design in which a patient serves as his own control is used in phase II studies ( Figure 1 ). The advantage of this design compared to a simple parallel design is a reduction in intra-subject variability and a corresponding reduction in sample size.
Phase II studies should also involve evaluations in special populations. The high degree of co-morbid heart disease, hypertension and diabetes in ED patients ( Figure 2 ) may warrant early stage characterization of the potential cardiac or metabolic effects of novel agents. These should include pharmacodynamic interactions as well as the traditional pharmacokinetic analyses.
For non-life-threatening diseases there is a regulatory requirement to conduct two or more`de®ni-tive' or`pivotal' studies in appropriately selected patient groups. Phase III trials are typically designed as multi-centre, randomized, prospective studies using active drug and a double-blind placebo control. Traditionally, Phase III studies have used a parallel-design, although crossover studies and a hybrid parallel-crossover design have been used (Figure 1 ).
Although not required for regulatory approval, a comparator drug may be included to help with pricing. All studies should be prospective with inclusion and exclusion criteria, baseline characteristics and primary and secondary endpoints de®ned in advance. The duration of treatment may vary from a few weeks to 6 months or more and will often involve an open-label extension phase to accrue additional safety data.
Phase IV studies are undertaken during the registration process or subsequent to approval. In general these are designed to increase the understanding of the overall treatment pro®le in the target population and may not include all the controls (eg placebo-blinding and baseline measurements). Increasingly, the healthcare environment requires outcome assessment in long-term studies to generate data about the impact of the new therapy on healthcare economics.
Clinical trial design options
The incorporation of randomization and placebo controls has become standard practice. As stated earlier, although there is no absolute regulatory requirement for the inclusion of a comparator, one is sometimes included for pricing purposes and for the inclusion of relevant data in the product label. 
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Essentially, larger trials are based on one of two basic templates, given below. In the simplest parallel design patients are randomly assigned to one or two or more parallel treatment arms for the duration of the study period (usually 1 ± 6 months) ( Figure 3 ). Each patient is exposed to one treatment condition only and comparisons are made between groups at various time points. Treatment-induced changes are assessed by analysis of between-group differences following treatment. Results can also be analysed relative to baseline. Baseline assessments are routinely obtained to ensure that the treatment groups are equivalent prior to randomization.
The parallel treatment phase, usually doubleblind, is frequently preceded by a single-blind placebo or`no treatment' run-in phase to establish a reproducible baseline prior to randomization. This run-in period can also be used to screen out patients who are most susceptible to placebo effects. At this stage, patients are then typically assigned to the double blind, randomized phase of the study.
An alternative approach is based on a crossover, within-subject design (Figure 4 ). In this design each patient serves as his own control. The advantage of this approach is a potential reduction in patient variability Ð a feature that may result, however, in a bias towards a positive outcome. As such, this design is generally favoured in early stage clinical studies (phases I and II), and may not be suf®cient as the basis for regulatory approval. Another potential problem with crossover designs is the likelihood of carryover effects from one treatment phase to the next. To minimize this potential confound, an adequate`wash-out' period should be included between treatment phases (eg one month). If more than two treatment arms are included in the study design, this may result in a lengthy total duration (eg 12 months or more), which may limit the feasibility of the study. 
Following the double-blind phase, it is common practice in ED trials for patients to be offered entry in an open-label extension period (6 ± 24 months) while receiving the study drug. The accepted rationale is that, because the study is open label, there is an incentive for patients to remain in the study, leading to the accumulation of important long-term safety and ef®cacy data. In addition, investigators may acquire ®rst-hand experience using the drug in a`real life' setting. Although this type of study is of value, an alternative study design for the future is show in Figure 5 .
The type of study represented in Figure 5 is an extension of the double-blind parallel design shown in Figure 3 . At the end of the initial double-blind treatment period, patients in both active and placebo arms are re-randomized into a long-term safety' study at a ratio of 75% active: 25% placebo, and followed for an extended period (6 ± 24 months). In addition to accumulating additional safety data, an assessment of long-term ef®cacy and discontinuation rates could also be obtained. Results obtained from this type of study would potentially have greater scienti®c credibility and regulatory acceptance than traditional open-label extension studies.
Study population
Several general principles govern the choice of study population when designing clinical trials:
The study population should be representative of the overall target population to which the therapy is directed. Under these conditions, the trial is more likely to be predictive of the`real world' effect. To ensure this, patient age, overall health status, concomitant medications, co-morbidities and severity and duration of ED must be incorporated into the trial design. The ED status of the study population must be well characterized and de®ned. In order for the trial results to be easily interpreted by practitioners, disease manifestations before and after drug treatment must be meticulously de®ned. This level of de®nition is achieved by patient selection based on unambiguous inclusion and exclusion criteria. A reasonable balance must be struck between ensuring the safety of the patients in the study and making the study representative of the`real world'. In essence, the trial population should be suf®ciently broad to represent the group of patients who may eventually bene®t, but it should not be so broad as to include patients who are clearly and directly at high risk when exposed to the treatment. The impact of treatment on co-morbidities should also be evaluated. There is a high degree of comorbid heart disease, hypertension and diabetes (controlled or uncontrolled) in ED patients. The impact of therapy on the natural progression of these associated disorders andaor pharmacodynamic interactions with existing therapy should also be considered.
De®nition of disease state and trial population
Guidelines for inclusion and exclusion criteria are described in detail elsewhere. 1 The inclusion criteria are obviously designed to ensure that the study population is likely to be representative of the potential population or sub-populations in the Figure 5 Potential model for double-blind extension study.
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M Wyllie community. The exclusion criteria on the other hand are meant to strictly de®ne the study population and to provide safeguards against involving patients who are inherently at high risk. There is, however, one major issue relating to the choice of the exclusion criteria. It is clear that there is some degree of inherent con¯ict between the safety of patients in trials and studying the therapy in a representative patient population. In particular, patients with extensive cardiovascular disease may not be appropriate for inclusion in controlled clinical trials and such patients invariably will demand access to the drug post approval. Assessing the cardiovascular risk of novel therapies is further compounded by the probability that sexual activity itself may precipitate cardiovascular adverse events.
The classical cardiovascular exclusion criteria are unstable angina or history of stroke, MI or lifethreatening arrhythmia within the previous 6 months, hypotension or uncontrolled hypertension. However, faced with the high degree of cardiovascular co-morbidity in ED patients (Figure 2 ) and the ®nding that vasodilators such as sildena®l can alter blood pressure control in controlled hypertensives, 2,3 cardiovascular risk assessment has become an increasingly important focus of attention. An example of a recent series of trials on the assessment of pharmacodynamic interaction between phentolamine and agents used for blood pressure control is shown in Table 1 . It is likely that there will be an increasing regulatory requirement for data from such studies.
Assessment of treatment outcome
When determining bene®t ± risk, both pre-treatment and post-treatment assessments should be standardized, validated and accepted by the scienti®c community. In the absence of such standardization, comparing data from one clinical trial to another is of little value and should be viewed with caution. Whereas in other areas of medicine there has been a considerable degree of standardization and acceptance of outcome measures, this has not been the case in ED. Among the outcome variables used most frequently in ED trials are objective measures of penile rigidity or tumescence (eg Rigiscan), patientbased questionnaires or diary reports of sexual function, partner assessments and global ratings of clinical improvements. The relative advantages and limitations of these measurements are described in detail elsewhere 1 and thus are only summarized below.
Although several methods for objective measure of penile engorgement and rigidity have been described, the most widely used is Rigiscan. This tool has been featured in the clinical development programmes for alprostadil, apomorphine and sildena®l. Perhaps the major limitation of this technique is the underlying assumption that there is a correlation between radial and axial rigidity. However, despite these limitations, Rigiscan continues to play an important role, particularly in the early phases of clinical development. Other physiological measurements include volumetric plethysmography, electromechanical strain gauges and the erectiometer.
The self-report measures of sexual function are divided into three major categories: self-administered questionnaires (SAQs); daily diariesaevent logs; and structured interviews. Once again, the reader is referred elsewhere for a more in-depth analysis. 1 All three methods are being used routinely in clinical trials, although there is a trend favouring SAQs, presumably because they have the advantage of providing standardization and are a relatively cost-ef®cient method of assessing historical and current sexual history.
The most widely used indices are: 
Adverse assessment monitoring
With the advent of an increasing collection of potential drugs for the treatment of ED in clinical development, assessment of risk ± bene®t is assuming an even greater importance. It is obvious that this must go beyond the traditional`cataloguing' of adverse events and an attempt to index the impact of therapy on co-morbidities should be made. Given the high degree of association between ED and hypertension and diabetes (Figure 2 ), it would be reasonable for the patient and physician to be forewarned about the impact of the proposed ED treatment on his blood pressure control and diabetic control. Certainly, there is evidence that the 
Conclusions
Ultimately there is a requirement for clinical trials to be predictive of the likely response in the real world. To achieve this, the trials must obviously be designed to provide a realistic assessment of ef®cacy and side effects. Additionally, given the concerns about cardiovascular risk arising from renewed sexual activity or the use of oral vasodilators, there is likely to be an increasing focus on this aspect of clinical pro®ling. Information on the impact, whether bene®cial or negative, of potential therapies on agents used to control associated co-morbidities would be of equal value.
